Clicky

AstraZeneca PLC(ZEG) News

Date Title
Apr 21 AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
Apr 21 Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
Apr 21 AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Apr 21 ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
Apr 1 AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
Apr 1 AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
Apr 1 Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins
Apr 1 FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
Mar 31 Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
Mar 31 FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
Mar 31 ​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
Mar 31 JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Mar 31 IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
Mar 28 Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds?
Mar 27 Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
Mar 27 How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
Mar 26 AstraZeneca says new results reinforce Tagrisso as backbone therapy
Mar 26 Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know
Mar 25 New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
Mar 14 AstraZeneca Stock Scores RS Rating Upgrade